Eighteen-month hybrid closed-loop use in very young children with type 1 diabetes: a single-arm multicenter trial: A Single-Arm Multicenter Trial
Gespeichert in:
| Titel: | Eighteen-month hybrid closed-loop use in very young children with type 1 diabetes: a single-arm multicenter trial: A Single-Arm Multicenter Trial |
|---|---|
| Autoren: | Julia Ware, Janet M. Allen, Charlotte K. Boughton, Malgorzata E. Wilinska, Sara Hartnell, Ajay Thankamony, Carine de Beaufort, Fiona M. Campbell, Elke Fröhlich-Reiterer, Maria Fritsch, Sabine E. Hofer, Thomas M. Kapellen, Birgit Rami-Merhar, Martin Tauschmann, Roman Hovorka, Carlo L Acerini, Charlotte K Boughton, Klemen Dovc, Gianluca Musolino, Malgorzata E Wilinska, Janet M Allen, Yue Ruan, Nicole Ashcroft, Matthew Haydock, Catherine Hill, Hildegard Jasser-Nitsche, Julia K Mader, Kerstin Faninger, Thomas M Kapellen, Heike Bartelt, Alena Thiele, Gabriele Berger, Nicole Blauensteiner, Renata Gellai, Katrin Nagl, Sarah Cvach, Sonja Katzenbeisser-Pawlik, Sabine E Hofer, Daniela Abt, Anita Malik, Barbara Lanthaler, Matthias Wenzel, Fiona Campbell, James Yong, Emily Metcalfe, Majorie Allen, Sarah Ambler, Saima Waheed, Jane Exall, Joseph Tulip, Ulrike Schierloh, Muriel Fichelle, Dominique Schaeffer, Julia Lawton, David Rankin, Ruth Hart, Barbara Kimbell, Stéphane Roze, Timothy Jones, Chris Patterson, Peter Adolfsson |
| Weitere Verfasser: | Clinical sciences, Faculty of Medicine and Pharmacy, DSpace at Cambridge pro (8.1) |
| Quelle: | Diabetes Care |
| Verlagsinformationen: | American Diabetes Association, 2024. |
| Publikationsjahr: | 2024 |
| Schlagwörter: | Male, Blood Glucose, Cross-Over Studies, Child, preschool, Diabetes Mellitus, Type 1/drug therapy, Infant, Hypoglycemic Agents/administration & dosage, Blood Glucose/drug effects, Diabetes Mellitus, Type 1, Insulin Infusion Systems, Child, Preschool, Humans, Hypoglycemic Agents, Insulin, Original Article, Female, Child, Insulin/administration & dosage |
| Beschreibung: | Objective We aimed to evaluate the longer-term safety and efficacy of hybrid closed‑loop therapy in very young children with type 1 diabetes (T1D). Research Design and Methods Following a 16-week multi-national, randomized crossover trial comparing hybrid closed-loop (CL) with sensor-augmented pump (SAP) therapy in 74 very young children aged 1-7 years with T1D, participants were invited to an extension phase using CL for a further 18 months. Outcomes were compared to the primary phase SAP period and primary phase CL period. Results After the primary study phase, 60 participants were eligible to enroll in the extension. Of these, 49 consented (mean±SD age 6.6±1.5 years) to continue use of CL for 18 months. Percentage time in range (TIR) 3.9‑10.0mmol/L was 8.4 percentage points (95% CI 6.7 to 10.1; p |
| Publikationsart: | Article Other literature type |
| Dateibeschreibung: | application/pdf |
| ISSN: | 1935-5548 0149-5992 |
| DOI: | 10.2337/figshare.27040651 |
| DOI: | 10.2337/dc24-1313 |
| DOI: | 10.2337/figshare.27040651.v1 |
| DOI: | 10.17863/cam.114848 |
| Zugangs-URL: | https://pubmed.ncbi.nlm.nih.gov/39418532 https://biblio.vub.ac.be/vubir/(2e15341f-19ed-4deb-8702-8787767ae7f0).html |
| Rights: | CC BY NC SA CC BY URL: https://www.diabetesjournals.org/journals/pages/license |
| Dokumentencode: | edsair.doi.dedup.....97d34b0b124dd7cbc889b3c24cbb0f70 |
| Datenbank: | OpenAIRE |
Nájsť tento článok vo Web of Science | Abstract: | Objective We aimed to evaluate the longer-term safety and efficacy of hybrid closed‑loop therapy in very young children with type 1 diabetes (T1D). Research Design and Methods Following a 16-week multi-national, randomized crossover trial comparing hybrid closed-loop (CL) with sensor-augmented pump (SAP) therapy in 74 very young children aged 1-7 years with T1D, participants were invited to an extension phase using CL for a further 18 months. Outcomes were compared to the primary phase SAP period and primary phase CL period. Results After the primary study phase, 60 participants were eligible to enroll in the extension. Of these, 49 consented (mean±SD age 6.6±1.5 years) to continue use of CL for 18 months. Percentage time in range (TIR) 3.9‑10.0mmol/L was 8.4 percentage points (95% CI 6.7 to 10.1; p |
|---|---|
| ISSN: | 19355548 01495992 |
| DOI: | 10.2337/figshare.27040651 |